Bioreducible micelles self-assembled from amphiphilic hyperbranched multiarm copolymer for glutathione-mediated intracellular drug delivery

Reductively-sheddable cationic nanocarriers for dual chemotherapy and gene therapy with enhanced release

The development of a versatile strategy to synthesize cationic nanocarriers capable of co-delivery and enhanced release of drugs and oligonucleotides is promising for synergic dual chemotherapy and gene therapy. Herein, we report a novel cationic amphiphilic diblock copolymer having a single reduction-responsive disulfide linkage at a junction between a FDA-approved polylactide (PLA) block and a cationic methacrylate block (C-ssABP). The amphiphilic design of the C-ssABP enables the formation of cationic micellar aggregates possessing hydrophobic PLA cores, encapsulating anticancer drugs; cationic coronas, ensuring complementary complexation with negatively-charged oligonucleotides through electrostatic interactions; and disulfides at interfaces, leading to enhanced release of both encapsulated drugs and complexed oligonucleotides. The reduction-responsive intracellular trafficking results from flow cytometry, confocal laser scanning microscopy, and cell viability, as well as in vitro gene transfection assay suggest that C-ssABP offers versatility as an effective nanocarrier platform for dual chemotherapy and gene therapy.

Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery

Bioreducible carboxymethyl dextran (CMD) derivatives are synthesized by the chemical modification of CMD with lithocholic acid (LCA) through a disulfide linkage. The hydrophobic nature of LCA allows the conjugates (CMD-SS-LCAs) to form self-assembled nanoparticles in aqueous conditions. Depending on the degree of LCA substitution, the particle diameters range from 163 to 242 nm. Doxorubicin (DOX), chosen as a model anticancer drug, is effectively encapsulated into the nanoparticles with high loading efficiency (>70%). In vitro optical imaging tests reveal that the fluorescence signal of DOX quenched in the bioreducible nanoparticles is highly recovered in the presence of glutathione (GSH), a tripeptide capable of reducing disulfide bonds in the intracellular compartments. Bioreducible nanoparticles rapidly release DOX when they are incubated with 10 mm GSH, whereas the drug release is greatly retarded in physiological buffer (pH 7.4). DOX-loaded bioreducible nanoparticles exhibit higher toxicity to SCC7 cancer cells than DOX-loaded nanoparticles without the disulfide bond. Confocal laser scanning microscopy observation demonstrate that bioreducible nanoparticles can effectively deliver DOX into the nuclei of SCC7 cells. In vivo biodistribution study indicates that Cy5.5-labeled CMD-SS-LCAs selectively accumulate at tumor sites after systemic administration into tumor-bearing mice. Notably, DOX-loaded bioreducible nanoparticles exhibit higher antitumor efficacy than reduction-insensitive control nanoparticles. Overall, it is evident that bioreducible CMD-SS-LCA nanoparticles are useful as a drug carrier for cancer therapy.

Synthesis, Self-Assembly, and Multi-Stimuli Responses of a Supramolecular Block Copolymer

A supramolecular block copolymer is prepared by the molecular recognition of nucleobases between poly(2-(2-methoxyethoxy)ethyl methacrylate-co-oligo(ethylene glycol) methacrylate)-SS-poly(ε-caprolactone)-adenine (P(MEO2 MA-co-OEGMA)-SS-PCL-A) and uracil-terminated poly(ethylene glycol) (PEG-U). Because the block copolymer is linked by the combination of covalent (disulfide bond) and noncovalent (AU) bonds, it not only has similar properties to conventional covalently linked block copolymers but also possesses a dynamic and tunable nature. The copolymer can self-assemble into micelles with a PCL core and P(MEO2 MA-co-OEGMA)/PEG shell. The size and morphologies of the micelles/aggregates can be adjusted by altering the temperature, pH, salt concentration, or adding dithiothreitol (DTT) to the solution. The controlled release of Nile red is achieved at different environmental conditions.

Reduction-responsive polymeric micelles and vesicles for triggered intracellular drug release

SIGNIFICANCE

The therapeutic effects of current micellar and vesicular drug formulations are restricted by slow and inefficient drug release at the pathological site. The development of smart polymeric nanocarriers that release drugs upon arriving at the target site has received a tremendous amount of attention for cancer therapy.

RECENT ADVANCES

Taking advantage of a high reducing potential in the tumor tissues and in particular inside the tumor cells, various reduction-sensitive polymeric micelles and vesicles have been designed and explored for triggered anticancer drug release. These reduction-responsive nanosystems have demonstrated several unique features, such as good stability under physiological conditions, fast response to intracellular reducing environment, triggering drug release right in the cytosol and cell nucleus, and significantly improved antitumor activity, compared to traditional reduction-insensitive counterparts.

CRITICAL ISSUES

Although reduction-sensitive micelles and polymersomes have accomplished rapid intracellular drug release and enhanced in vitro antitumor effect, their fate inside the cells including the mechanism, site, and rate of reduction reaction remains unclear. Moreover, the systemic fate and performance of reduction-sensitive polymeric drug formulations have to be investigated.

FUTURE DIRECTIONS

Biophysical studies should be carried out to gain insight into the degradation and drug release behaviors of reduction-responsive nanocarriers inside the tumor cells. Furthermore, novel ligand-decorated reduction-sensitive nanoparticulate drug formulations should be designed and explored for targeted cancer therapy in vivo.

In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug

In vivo monitoring of the biodistribution and activation of prodrugs is urgently required. Near infrared (NIR) fluorescence-active fluorophores with excellent photostability are preferable for tracking drug release in vivo. Herein, we describe a NIR prodrug DCM-S-CPT and its polyethylene glycol-polylactic acid (PEG-PLA) loaded nanoparticles as a potent cancer therapy. We have conjugated a dicyanomethylene-4H-pyran derivative as the NIR fluorophore with camptothecin (CPT) as the anticancer drug using a disulfide linker. In vitro experiments verify that the high intracellular glutathione (GSH) concentrations in tumor cells cause cleavage of the disulfide linker, resulting in concomitantly the active drug CPT release and significant NIR fluorescence turn-on with large Stokes shift (200 nm). The NIR fluorescence of DCM-S-CPT at 665 nm with fast response to GSH can act as a direct off-on signal reporter for the GSH-activatable prodrug. Particularly, DCM-S-CPT possesses much better photostability than ICG, which is highly desirable for in situ fluorescence-tracking of cancer chemotherapy. DCM-S-CPT has been successfully utilized for in vivo and in situ tracking of drug release and cancer therapeutic efficacy in living animals by NIR fluorescence. DCM-S-CPT exhibits excellent tumor-activatable performance when intravenously injected into tumor-bearing nude mice, as well as specific cancer therapy with few side effects. DCM-S-CPT loaded in PEG-PLA nanoparticles shows even higher antitumor activity than free CPT, and is also retained longer in the plasma. The tumor-targeting ability and the specific drug release in tumors make DCM-S-CPT as a promising prodrug, providing significant advances toward deeper understanding and exploration of theranostic drug-delivery systems.

Dually degradable click hydrogels for controlled degradation and protein release

Crosslinks that can undergo click bond cleavage and ester hydrolysis were incorporated to design glutathione-sensitive, dually degradable hydrogels for degradation-mediated, controlled release of cargo molecules.

Core-cross-linked micellar nanoparticles from a linear-dendritic prodrug for dual-responsive drug delivery

A pH-responsive polymeric prodrug was cross-linked by disulfide formation, and the formed nanoparticles were systematically investigated as a novel drug formulation.

One-step sonochemical preparation of redox-responsive nanocapsules for glutathione mediated RNA release

A simple and reproducible sonochemical method is described to achieve redox-responsive nanocapsules based on intracellular glutathione levels for enhanced and sustained RNA delivery.

Hyperbranched polyester nanorods with pyrrolo[2,1-a]isoquinoline end groups for fluorescent recognition of Fe3+

Novel hyperbranched polyester nanorods HBPE-CICA₆ and HBPE-CICA₂ were obtained and used to establish a highly sensitive fluorescent sensor for Fe³⁺ ions.

Synthesis of a smart gold nano-vehicle for liver specific drug delivery

Targeting drug formulations to specific tissues and releasing the bioactive content in response to a certain stimuli remains a significant challenge in the field of biomedical science. We have developed a nanovehicle that can be used to deliver "drugs" to "specific" tissues. For this, we have simultaneously modified the surface of the nanovehicle with "drugs" and "tissue-specific ligands". The "tissue-specific ligands" will target the nanovehicle to the correct tissue and release the "drug" of interest in response to specific stimuli. We have synthesised a "lactose surface-modified gold nanovehicle" to target liver cells and release the model fluorescent drug (coumarin derivative) in response to the differential glutathione concentration (between blood plasma and liver cells). Lactose is used as the liver-specific targeting ligand given the abundance of L-galactose receptors in hepatic cells. The coumarin derivative is used as a fluorescent tag as well as a linker for the attachment of various biologically relevant molecules. The model delivery system is compatible with a host of different ligands and hence could be used to target other tissues as well in future. The synthesised nanovehicle was found to be non-toxic to cultured human cell lines even at elevated non-physiological concentrations as high as 100 μg/mL. We discover that the synthesised gold-based nanovehicle shows considerable stability at low extracellular glutathione concentrations; however coumarin is selectively released at high hepatic glutathione concentration.

Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery

We report herein a straightforward and label-free approach to prepare luminescent mesoporous silica nanoparticles. We found that calcination at 400 °C can grant mesoporous organosilica nanoparticles with strong fluorescence of great photo- and chemical stability. The luminescence is found to originate from the carbon dots generated from the calcination, rather than the defects in the silica matrix as was believed previously. The calcination does not impact the particles' abilities to load drugs and conjugate to biomolecules. In a proof-of-concept study, we demonstrated that doxorubicin (Dox) can be efficiently encapsulated into these fluorescent mesoporous silica nanoparticles. After coupled to c(RGDyK), the nanoconjugates can efficiently home to tumors through interactions with integrin α_vβ₃ overexpressed on the tumor vasculature. This calcination-induced luminescence is expected to find wide applications in silica-based drug delivery, nanoparticle coating, and immunofluorescence imaging.

Bioreducible PAA-g-PEG graft micelles with high doxorubicin loading for targeted antitumor effect against mouse breast carcinoma

Nanomaterials have demonstrated to be promising to deliver a chemotherapeutic drug deeply into the tumor for improving the anticancer efficacy. In this study, eight kinds of bioreducible PAA-g-PEG graft copolymeric micelles were prepared, and the anticancer drug DOX was stably encapsulated in the micelles. Benefited by the hydrophobic interaction and π-π stacking between aromatic structure of DOX and phenyl of PAA in the micelle core, high drug loading content more than 50 wt/wt % could be achieved. Drugs released from micelles in a reduction-sensitive manner, and effectively inhibit the growth of 4T1 mouse breast cancer cells in vitro. In the 4T1 tumor-bearing nude mice breast carcinoma subcutaneous model, the DOX-incorporated micelles showed much stronger accumulation in tumor than DOX·HCl, and reduced distribution in other main organs. The antitumor effect of the micelles was significantly better than DOX·HCl, as confirmed by tumor volume and body weight changes of the tumor-bearing Balb/c mice, as well as survive study. Encapsulation of DOX in the micelles improved the bioavailability of the drugs through the accumulation in tumor by passive targeting, greatly decreased organ damage due to cancer cell wild growth and metastasis, and depressed the toxicity of DOX on the heart and other organs.

Reduction-sensitive Nanosystems for Active Intracellular Drug Delivery

The past several years have witnessed explosive progress in reduction-sensitive nanosystems that are stable under physiological conditions, but rapidly destabilized under a reducing environment for “active” intra-cellular drug delivery. The uniqueness of the disulfide chemistry has enabled versatile design of smart nanosystems ranging from reduction-sensitive degradable micelles, polymersomes, nanogels and capsules to nanoparticles. This superior intra-cellular drug release approach has been shown to significantly enhance drug efficacy, overcome multi-drug resistance (MDR) and/or reduce drug- and carrier-associated side effects. In vivo studies have demonstrated that reduction-sensitive reversibly cross-linked nanosystems result in enhanced stability, longer circulation time, improved tumor-targetability and better therapeutic outcomes as compared to the non-cross-linked controls as well as to free drugs. It is anticipated that reduction-sensitive nanosystems will play a relevant role in the arena of targeted cancer therapy.

Polycarbonate-Based Brush Polymers with Detachable Disulfide-Linked Side Chains

We have successfully designed and synthesized polycarbonate-based brush polymers with detachable, disulfide-linked side chains. A polycarbonate backbone with disulfide-linked, hydroxyl-terminated pendant side chains was first prepared. Poly(trimethylene carbonate) or poly(l-lactide) brushes were then grafted from the terminal hydroxyl groups using an acid- or base-catalyzed ring-opening polymerization. Inspired by how cells use glutathione to mediated reduction of disulfides in cytoplasmic proteins, we also demonstrate that the side chains are easily detached under mild reductive conditions (e.g., with 1,4-dithiothreitol). l-Lactide and trimethylene carbonate were selected as model building blocks for the polymer grafts because of their commercial availability and routine use in polymeric drug delivery systems.

Galactose-based amphiphilic block copolymers: synthesis, micellization, and bioapplication

Redox-responsive amphiphilic diblock copolymers, poly(6-O-methacryloyl-D-galactopyranose-co-2-(N,N-dimethylaminoethyl) methacrylate)-b-poly(pyridyl disulfide ethyl methylacrylate) (P(MAGP-co-DMAEMA)-b-PPDSMA) were obtained by deprotection of poly((6-O-methacryloyl-1,2:3,4-di-O-isopropylidene-D-galactopyranose)-co-DMAEMA)-b-PPDSMA [P(MAlpGP-co-DMAEMA)-b-PPDSMA], which were prepared via reversible addition-fragmentation chain transfer (RAFT) polymerization of PDSMA using P(MAlpGP-co-DMAEMA) as macro-RAFT agent. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) studies showed that diblock copolymers P(MAGP-co-DMAEMA)-b-PPDSMA can self-assemble into micelles. Doxorubicin (DOX) could be encapsulated by P(MAGP-co-DMAEMA)-b-PPDSMA upon micellization and released upon adding glutathione (GSH) into the micelle solution. The galactose functional groups in the PMAGP block had specific interaction with HepG2 cells, and P(MAGP-co-DMAEMA)-b-PPDSMA can act as gene delivery vehicle. So, this kind of polymer has potential applications in hepatoma-targeting drug and gene delivery and biodetection.

Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers

Polymeric nanoparticles are promising candidates as drug and gene carriers. Among polymeric nanoparticles, those that are responsive to internal or external stimuli are of greater interest because they allow more efficient delivery of therapeutics to pathological regions. Stimulus-sensitive polymeric nanoparticles have been fabricated based on numerous nanostructures, including micelles, vesicles, crosslinked nanoparticles, and hybrid nanoparticles. The changes in chemical or physical properties of polymeric nanoparticles that occur in response to single, dual, or multiple stimuli endow these nanoparticles with the ability to retain cargoes during circulation, target the pathological region, and release their cargoes after cell internalization. This Review focuses on the most recent developments in the preparation of stimulus-sensitive polymeric nanoparticles and their applications in drug and gene delivery.

Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release

Redox and pH dual-responsive biodegradable micelles were developed based on poly(ethylene glycol)-SS-poly(2,4,6-trimethoxybenzylidene-pentaerythritol carbonate) (PEG-SS-PTMBPEC) copolymer and investigated for intracellular doxorubicin (DOX) release. PEG-SS-PTMBPEC copolymer with an Mn of 5.0-4.1kg/mol formed micellar particles with an average diameter of 140nm and a low polydispersity of 0.12. DOX was loaded into PEG-SS-PTMBPEC micelles with a decent drug loading content of 11.3wt.%. The in vitro release studies showed that under physiological conditions only ca. 24.5% DOX was released from DOX-loaded micelles in 21h. The release of DOX was significantly accelerated at pH5.0 or in the presence of 10mM glutathione (GSH) at pH7.4, in which 62.8% and 74.3% of DOX was released, respectively, in 21h. The drug release was further boosted under 10mM GSH and pH 5.0 conditions, with 94.2% of DOX released in 10h. Notably, DOX release was also facilitated by 2 or 4h incubation at pH 5.0 and then at pH 7.4 with 10mM GSH, which mimics the intracellular pathways of endocytosed micellar drugs. Confocal microscopy observation indicated that DOX was delivered and released into the nuclei of HeLa cells following 8h incubation with DOX-loaded PEG-SS-PTMBPEC micelles, while DOX was mainly located in the cytoplasm for reduction-insensitive PEG-PTMBPEC controls. MTT assays revealed that DOX-loaded PEG-SS-PTMBPEC micelles had higher anti-tumor activity than reduction-insensitive controls, with low IC50 of 0.75 and 0.60μg/mL for HeLa and RAW 264.7 cells, respectively, following 48h incubation. PEG-SS-PTMBPEC micelles displayed low cytotoxicity up to a concentration of 1.0mg/mL. These redox and pH dual-bioresponsive degradable micelles have appeared as a promising platform for targeted intracellular anticancer drug release.

Biocompatibility of engineered nanoparticles for drug delivery

The rapid advancement of nanotechnology has raised the possibility of using engineered nanoparticles that interact within biological environments for treatment of diseases. Nanoparticles interacting with cells and the extracellular environment can trigger a sequence of biological effects. These effects largely depend on the dynamic physicochemical characteristics of nanoparticles, which determine the biocompatibility and efficacy of the intended outcomes. Understanding the mechanisms behind these different outcomes will allow prediction of the relationship between nanostructures and their interactions with the biological milieu. At present, almost no standard biocompatibility evaluation criteria have been established, in particular for nanoparticles used in drug delivery systems. Therefore, an appropriate safety guideline of nanoparticles on human health with assessable endpoints is needed. In this review, we discuss the data existing in the literature regarding biocompatibility of nanoparticles for drug delivery applications. We also review the various types of nanoparticles used in drug delivery systems while addressing new challenges and research directions. Presenting the aforementioned information will aid in getting one step closer to formulating compatibility criteria for biological systems under exposure to different nanoparticles.

Studies on the orthogonal assembly of β-cyclodextrin-poly (ε-caprolactone) and ferrocene-poly (ethylene oxide)

A biodegradable multi-arm polymer β-cyclodextrin-poly (ε-caprolactone) (CD-PCL) with a ``jellyfish-like'' structure was obtained, in which flexible and hydrophobic PCL arms were selectively grafted to the wide side of the hydrophilic torus-shaped β-CD. The amphiphilic "jellyfish-like'' polymer with a hollow cavity and hydrophobic tails could orthogonally self-assemble into a new amphiphilic supramolecular copolymer CD-PCL/FcPEG with poly (ethylene oxide) end-decorated by ferrocene (FcPEG) in aqueous solution based on terminal hydrophobic interactions. The chemical structures of CD-PCL and CD-PCL/FcPEG were characterized by IR, NMR and UV and their self-assembled structures in water were investigated by transmission electron microscopy (TEM) and dynamic light scattering (DLS). CD-PCL alone self-assembled into nano vesicles in water, while CD-PCL/FcPEG into nanospheres. The supramolecular nanospheres were further investigated by cyclic voltammogram. The results indicated that the ferrocenyl groups which were embedded into the hydrophobic core of the supramolecular nanospheres could not transmit electrons or carry out electrochemical oxidation and reduction reaction.

Alendronate-conjugated amphiphilic hyperbranched polymer based on Boltorn H40 and poly(ethylene glycol) for bone-targeted drug delivery

A novel type of alendronate(ALE)-conjugated amphiphilic hyperbranched copolymer based on a hydrophobic hyperbranched Boltorn H40 (H40) core with ALE targeting moiety and many hydrophilic poly(ethylene glycol) (PEG) arms was synthesized as a carrier for bone-targeted drug delivery. The star copolymer H40-star-PEG/ALE was characterized using nuclear magnetic resonance (NMR), Fourier transformed infrared spectroscopy (FTIR), and gel permeation chromatography (GPC) analysis. Benefiting from its highly branched structure, H40-star-PEG/ALE could form micelles in aqueous solution, which was confirmed by transmission electron microscopy (TEM) and dynamic light scattering (DLS) techniques. The cytotoxicity and hemolysis of the H40-star-PEG/ALE micelles were evaluated via methylthiazoletetrazolium (MTT) assay against NIH/3T3 normal cells and red blood cell (RBC) lysis assay, respectively. As a model anticancer drug, doxorubicin (DOX) was encapsulated into the H40-star-PEG/ALE micelles. The anticancer activity of DOX-loaded micelles was evaluated by MTT assay against an HN-6 human head and neck carcinoma cell line. The strong affinity of H40-star-PEG/ALE micelles to bone was confirmed by the hydroxyapatite (HA) binding assay. These results indicate that the H40-star-PEG/ALE micelles are highly promising bone-targeted drug carriers for skeletal metastases.